9 completed, 2 terminated, 1 unknown. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 9, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow reslizumab: new trials by email Literature Review of reslizumab trials Research Report on reslizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma reslizumab - Eosinophils, Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 391 | 2017-03-10 | 2022-12-14 |
| Effect of Reslizumab in Chronic Rhinosinusitis Reslizumab, Placebo - Sinusitis | Phase 3 | Unknown | Joshua S. Jacobs | 30 | 2016-06-01 | 2018-02-01 |
| Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Reslizumab, Placebo - Severe Persistent Asthma, Eosinophilic Bronchitis | Phase 2 / Phase 3 | Completed | McMaster University | 10 | 2015-10-01 | 2018-04-04 |
| An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils Reslizumab, Placebo, Non-Oral Corticosteroid (non-OCS) Asthma Medication - Asthma, Elevated Blood Eosinophils | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 177 | 2015-09-29 | 2021-11-09 |
| Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils Reslizumab, Placebo - Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 468 | 2015-09-28 | 2021-11-09 |
| Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 511 | 2012-02-01 | 2016-06-27 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Reslizumab - Eosinophilic Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1052 | 2011-06-01 | 2016-06-06 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 489 | 2011-04-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 464 | 2011-03-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 315 | 2011-02-01 | 2016-06-06 |
| Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis reslizumab - Eosinophilic Esophagitis | Phase 3 | Completed | Ception Therapeutics | 190 | 2008-07-01 | 2017-03-23 |
| Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Reslizumab, Saline - Eosinophilic Esophagitis | Phase 2 / Phase 3 | Completed | Ception Therapeutics | 227 | 2008-03-01 | 2016-09-02 |
Pulmonary Eosinophilia (5) · Asthma (4) · Eosinophilic Esophagitis (2) · Bronchiolitis Obliterans Syndrome (1) · Gastroesophageal Reflux (1) · Rhinitis (1) · Rhinosinusitis (1) · Sinusitis (1)
Teva Branded Pharmaceutical Products R&D, Inc. (8) · Ception Therapeutics (2) · Joshua S. Jacobs (1) · McMaster University (1)
United States (11) · Canada (8) · Belgium (6) · France (6) · Hungary (6) · Israel (6) · Poland (6) · Russia (6) · Argentina (5) · Czechia (5) · Germany (5) · Mexico (5) · Ukraine (5) · Australia (4) · Romania (4)
Joshua Jacobs, MD (1) · Parameswaran Nair, MD, PhD (1)
PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 32066536, PMID 22206777, PMID 27018175, PMID 27056586, PMID 28915080
2015 (2), 2016 (1)